Plain-English translation of NCT06360523 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
ProstateAI is a research study that compares how well artificial intelligence can detect prostate cancer on MRI scans compared to experienced radiologists. You would have your prostate MRI scanned and reviewed by both an AI system and a radiologist. The study then compares how well each approach identified cancer by looking at the results of your planned biopsy.
Doctors need better tools to spot prostate cancer early and accurately. This study explores whether artificial intelligence can help radiologists make faster, more reliable decisions about which men need biopsies, potentially improving care and reducing unnecessary procedures.
You likely qualify if…
You likely don't qualify if…
Your existing prostate MRI images will be reviewed twice — once by an artificial intelligence system and once by an experienced radiologist — without them knowing each other's results. Your doctor will use both reviews to plan your biopsy. After your biopsy is completed, the study team will compare how well the AI and the radiologist each identified cancer by checking the biopsy results.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Hong Kong
Sponsor
Chinese University of Hong Kong
Enrollment target
~368 participants
Started
June 2024
Primary completion
December 2027
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Peter Ka-Fung CHIU, FRCS, PhD
Chinese University of Hong Kong
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.